beta blocker: be contraindicated in myasthenia gravis

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents agent
Weight: 0.65
, high blood pressure
Weight: 0.63
, heart disease
Weight: 0.63
, vasodilator
Weight: 0.62
Siblings atenolol
Weight: 0.53
, lung cancer
Weight: 0.33
, cystic fibrosis
Weight: 0.33
, agonist
Weight: 0.32
, blood clot
Weight: 0.32

Related properties

Property Similarity
be contraindicated in myasthenia gravis 1.00
be contraindicated in copd 0.96
be contraindicated in in raynaud 0.96
be contraindicated in pheochromocytoma 0.96
be contraindicated in disease 0.96
be contraindicated in patients 0.95
be contraindicated in diabetes 0.94
be contraindicated in pregnancy 0.94
be contraindicated in cardiogenic shock 0.94
be contraindicated in edema 0.94

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Remarkability exclusitivity between siblings

0.08
Rule weight: 0.13
Evidence weight: 0.64
Similarity weight: 0.94
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.42
¬ Remarkable(atenolol, be contraindicated in pregnancy)

Remarkability from sibling implausibility

0.45
Rule weight: 0.60
Evidence weight: 0.80
Similarity weight: 0.94
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.42
Remarkable(atenolol, be contraindicated in pregnancy) ⋁
Evidence: 0.70
¬ Plausible(atenolol, be contraindicated in pregnancy)

Salient implies Plausible

0.18
Rule weight: 0.28
Evidence weight: 0.64
Similarity weight: 1.00
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.72
¬ Salient(beta blocker, be contraindicated in myasthenia gravis)

Similarity expansion

0.75
Rule weight: 0.85
Evidence weight: 0.92
Similarity weight: 0.96
Evidence: 0.86
Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.58
¬ Remarkable(beta blocker, be contraindicated in pheochromocytoma)
0.74
Rule weight: 0.85
Evidence weight: 0.90
Similarity weight: 0.96
Evidence: 0.86
Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.74
¬ Remarkable(beta blocker, be contraindicated in copd)
0.73
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.96
Evidence: 0.86
Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.79
¬ Remarkable(beta blocker, be contraindicated in in raynaud)
0.73
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.94
Evidence: 0.86
Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.63
¬ Remarkable(beta blocker, be contraindicated in pregnancy)
0.73
Rule weight: 0.85
Evidence weight: 0.91
Similarity weight: 0.94
Evidence: 0.86
Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.66
¬ Remarkable(beta blocker, be contraindicated in diabetes)
0.71
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.94
Evidence: 0.86
Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.79
¬ Remarkable(beta blocker, be contraindicated in cardiogenic shock)
0.67
Rule weight: 0.85
Evidence weight: 0.82
Similarity weight: 0.96
Evidence: 0.72
Salient(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.66
¬ Salient(beta blocker, be contraindicated in copd)
0.67
Rule weight: 0.85
Evidence weight: 0.81
Similarity weight: 0.96
Evidence: 0.72
Salient(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.66
¬ Salient(beta blocker, be contraindicated in in raynaud)
0.63
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.94
Evidence: 0.72
Salient(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.77
¬ Salient(beta blocker, be contraindicated in cardiogenic shock)
0.62
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.94
Evidence: 0.72
Salient(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.78
¬ Salient(beta blocker, be contraindicated in pregnancy)
0.62
Rule weight: 0.85
Evidence weight: 0.76
Similarity weight: 0.96
Evidence: 0.72
Salient(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.84
¬ Salient(beta blocker, be contraindicated in pheochromocytoma)
0.62
Rule weight: 0.85
Evidence weight: 0.75
Similarity weight: 0.96
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.50
¬ Plausible(beta blocker, be contraindicated in in raynaud)
0.61
Rule weight: 0.85
Evidence weight: 0.76
Similarity weight: 0.94
Evidence: 0.72
Salient(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.85
¬ Salient(beta blocker, be contraindicated in diabetes)
0.61
Rule weight: 0.85
Evidence weight: 0.74
Similarity weight: 0.96
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.53
¬ Plausible(beta blocker, be contraindicated in copd)
0.60
Rule weight: 0.85
Evidence weight: 0.73
Similarity weight: 0.96
Evidence: 0.40
Typical(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.44
¬ Typical(beta blocker, be contraindicated in in raynaud)
0.57
Rule weight: 0.85
Evidence weight: 0.70
Similarity weight: 0.96
Evidence: 0.40
Typical(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.50
¬ Typical(beta blocker, be contraindicated in copd)
0.56
Rule weight: 0.85
Evidence weight: 0.70
Similarity weight: 0.94
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.60
¬ Plausible(beta blocker, be contraindicated in cardiogenic shock)
0.53
Rule weight: 0.85
Evidence weight: 0.66
Similarity weight: 0.94
Evidence: 0.40
Typical(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.56
¬ Typical(beta blocker, be contraindicated in cardiogenic shock)
0.52
Rule weight: 0.85
Evidence weight: 0.66
Similarity weight: 0.94
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.70
¬ Plausible(beta blocker, be contraindicated in pregnancy)
0.50
Rule weight: 0.85
Evidence weight: 0.61
Similarity weight: 0.96
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.79
¬ Plausible(beta blocker, be contraindicated in pheochromocytoma)
0.50
Rule weight: 0.85
Evidence weight: 0.62
Similarity weight: 0.94
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.76
¬ Plausible(beta blocker, be contraindicated in diabetes)
0.44
Rule weight: 0.85
Evidence weight: 0.55
Similarity weight: 0.94
Evidence: 0.40
Typical(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.74
¬ Typical(beta blocker, be contraindicated in pregnancy)
0.41
Rule weight: 0.85
Evidence weight: 0.52
Similarity weight: 0.94
Evidence: 0.40
Typical(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.80
¬ Typical(beta blocker, be contraindicated in diabetes)
0.40
Rule weight: 0.85
Evidence weight: 0.49
Similarity weight: 0.96
Evidence: 0.40
Typical(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.85
¬ Typical(beta blocker, be contraindicated in pheochromocytoma)

Typical and Remarkable implies Salient

0.13
Rule weight: 0.14
Evidence weight: 0.90
Similarity weight: 1.00
Evidence: 0.72
Salient(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.40
¬ Typical(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis)

Typical implies Plausible

0.39
Rule weight: 0.48
Evidence weight: 0.80
Similarity weight: 1.00
Evidence: 0.51
Plausible(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.40
¬ Typical(beta blocker, be contraindicated in myasthenia gravis)

Typicality and Rermarkability incompatibility between siblings

0.04
Rule weight: 0.14
Evidence weight: 0.29
Similarity weight: 0.94
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis) ⋁
Evidence: 0.82
¬ Typical(atenolol, be contraindicated in pregnancy)